TABLE 2.
Summary of cell lines and treatments used in this study
| Cell line(s) | Description (reference or source) | Treatment(s) | Expt(s) |
|---|---|---|---|
| MDCK (hTWIST1 O/E) | MDCK cells stably overexpressing hTWIST1 (54) | Transfection with pCMV-XX-HA constructs for partners | IP MS, co-IP validation |
| C3H10T1/2 | Mesenchymal stem cells (ATCC) | Transfection with BiFC constructs | BiFC, scratch assay |
| mESC | EB formation and doxycycline induction | qPCR analysis or RNA-seq | |
| A2loxcre | 41 | ||
| Twist1−/− and Twist1+/− | Derived from A2loxcre by CRISPR editing | ||
| T0, TT, T3, T4, and T12 | Derived from A2loxcre by induced cassette exchange; doxycycline inducible |